ZNTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Zentalis Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.30+0.17 (+7.98%)
Close on Oct 19, 2026
- Market cap
- $164.05M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.81 (+54.36%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Zentalis Pharmaceuticals, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$128.13M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$153.37M
TTM Q2 2026
Free cash flow
-$128.13M
TTM Q2 2026
EPS, diluted
-$1.95
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $164.05M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.14
- Dividend yield
- –
- Free cash flow yield
- -78.10%
Fundamentals
- Revenue
- $0
- Net income
- -$139.55M
- EPS, diluted
- -$1.95
- Free cash flow
- -$128.13M
- Book value per share
- $2.01
- Diluted shares
- 71M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$153.37M
Net income
-$139.55M
EPS, diluted
-$1.95
Free cash flow
-$128.13M
Reported periodTrailing twelve months